A randomised controlled trial of fibrinogen concentrate during scoliosis surgery.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 32500569.
- Also identified by DOI 10.1111/anae.15124.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bleeding and blood transfusion are common after scoliosis surgery. Fibrinogen is essential for blood clot formation and depletes quickly during haemorrhage. We randomly allocated 102 children 12-18 years old having surgery for idiopathic scoliosis, 51 to intra-operative fibrinogen concentrate 30 mg.kg<sup>-1</sup> (maximum 2 g) and 51 to saline placebo. Fibrinogen reduced peri-operative blood loss by a median (95%CI) volume of 155 (5-320) ml, from a median (IQR [range]) of 1035 (818-1420 [400-3030]) ml to 885 (755-1155 [270-2645]) ml, p = 0.04. Seven and four children received allogeneic red blood cell transfusion after fibrinogen and placebo, respectively, p = 0.34. There were no side-effects.
Medical subject headings
- Blood Loss, Surgical
- Fibrinogen
- Hemostatics
- Intraoperative Care
- Postoperative Hemorrhage
- Scoliosis